BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 18062750)

  • 1. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
    Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB; Glück S
    Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab cardio-oncology: lessons learned.
    Frankel C
    Clin J Oncol Nurs; 2010 Oct; 14(5):630-40. PubMed ID: 20880820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab-induced cardiotoxicity.
    Moss LS; Starbuck MF; Mayer DK; Harwood EB; Glotzer J
    Oncol Nurs Forum; 2009 Nov; 36(6):676-85. PubMed ID: 19887355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-associated cardiotoxicity.
    Keefe DL
    Cancer; 2002 Oct; 95(7):1592-600. PubMed ID: 12237930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiac safety of trastuzumab in the treatment of breast cancer.
    Chien AJ; Rugo HS
    Expert Opin Drug Saf; 2010 Mar; 9(2):335-46. PubMed ID: 20175700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
    Suter TM; Cook-Bruns N; Barton C
    Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab versus lapatinib: the cardiac side of the story.
    Azim H; Azim HA; Escudier B
    Cancer Treat Rev; 2009 Nov; 35(7):633-8. PubMed ID: 19640652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical cardiac tolerability of trastuzumab.
    Perez EA; Rodeheffer R
    J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of cardiac dysfunction after herceptin treatment in patients with metastatic breast cancer by echocardiography].
    Hattori K; Nishi Y; Nakamura S; Misao H; Kikuchi M; Sasaki R; Takeda K
    Rinsho Byori; 2007 Feb; 55(2):120-5. PubMed ID: 17390714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
    Fiúza M
    Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
    Morris PG; Hudis CA
    J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cardiac dysfunction induced by trastuzumab].
    Campone M; Bourbouloux E; Fumoleau P
    Bull Cancer; 2004 Nov; 91 Suppl 3():166-73. PubMed ID: 15899624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Popat S; Smith IE
    Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer.
    Sandoo A; Kitas GD; Carmichael AR
    Anticancer Res; 2014 Mar; 34(3):1147-51. PubMed ID: 24596352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.